{"nctId":"NCT01076088","briefTitle":"Safety and Efficacy of Co-Administration of Sitagliptin and Metformin in China (MK-0431-121)","startDateStruct":{"date":"2010-11-15","type":"ACTUAL"},"conditions":["Type 2 Diabetes Mellitus"],"count":744,"armGroups":[{"label":"Sitagliptin 50 mg + metformin 500 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Sitagliptin 50 mg","Drug: Metformin 500 mg"]},{"label":"Sitagliptin 50 mg + metformin 850 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Sitagliptin 50 mg","Drug: Metformin 850 mg"]},{"label":"Metformin 500 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Metformin 500 mg"]},{"label":"Metformin 850 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Metformin 850 mg"]},{"label":"Sitagliptin 100 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Sitagliptin 100 mg"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Sitagliptin 50 mg","otherNames":["Januvia®, Tesavel®, Xelevia®, Ristaben®"]},{"name":"Metformin 500 mg","otherNames":["Fortamet®, Glucophage®, Glucophage® XR, Glumetza®, Riomet®, Metgluco®, Glycoran®"]},{"name":"Sitagliptin 100 mg","otherNames":["Januvia®, Tesavel®, Xelevia®, Ristaben®"]},{"name":"Placebo","otherNames":[]},{"name":"Metformin 850 mg","otherNames":["Fortamet®, Glucophage®, Glucophage® XR, Glumetza®, Riomet®, Metgluco®, Glycoran®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* has type 2 diabetes mellitus\n* is male, a female who cannot have children, or a female who agrees to use birth control during the study\n* is not on an antihyperglycemic agent (AHA) (hemoglobin A1c \\[A1C\\] 7.5-11.0%) or on oral single AHA (A1C 7.0-10.5%) or low-dose AHA combination therapy (A1C 7.0-10.0%)\n\nExclusion Criteria:\n\n* Patient has type 1 diabetes mellitus or ketoacidosis\n* Patient is taking a dipeptidyl peptidase-4 (DPP-4) inhibitor (such as sitagliptin)\n* Patient is on a weight loss program not in the maintenance phase or on a weight loss medication\n* Patient has a history of liver disease, heart failure, heart disease, stroke, high blood pressure, blood disorders, or cancer\n* Patient is HIV positive\n* Patient is pregnant","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"78 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Hemoglobin A1C (A1C) at Week 24","description":"A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.67","spread":null},{"groupId":"OG001","value":"-1.83","spread":null},{"groupId":"OG002","value":"-1.29","spread":null},{"groupId":"OG003","value":"-1.56","spread":null},{"groupId":"OG004","value":"-0.99","spread":null},{"groupId":"OG005","value":"-0.59","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 2-hour Post Meal Glucose (2-h PMG) at Week 24","description":"Change from baseline in 2-h PMG at Week 24 is defined as Week 24 2-h PMG minus Week 0 2-h PMG.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-97.05","spread":null},{"groupId":"OG001","value":"-109.46","spread":null},{"groupId":"OG002","value":"-65.67","spread":null},{"groupId":"OG003","value":"-90.93","spread":null},{"groupId":"OG004","value":"-48.11","spread":null},{"groupId":"OG005","value":"-21.88","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24","description":"Change from baseline in FPG at Week 24 is defined as Week 24 FPG minus Week 0 FPG.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-39.38","spread":null},{"groupId":"OG001","value":"-47.74","spread":null},{"groupId":"OG002","value":"-33.66","spread":null},{"groupId":"OG003","value":"-39.63","spread":null},{"groupId":"OG004","value":"-21.86","spread":null},{"groupId":"OG005","value":"-11.93","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":122},"commonTop":["Diarrhoea","Hypoglycaemia","Nausea"]}}}